BackInsight Molecular Diagnostics Overview

Insight Molecular Diagnostics Other Liabilities

Track Insight Molecular Diagnostics's other liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Insight Molecular Diagnostics Other Liabilities History

Loading

Insight Molecular Diagnostics vs. peers: Other Liabilities Comparison

Loading

Insight Molecular Diagnostics Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Insight Molecular Diagnostics (IMDX) FAQ

As of the most recent data (September 2026), IMDX shows a other liabilities of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IMDX's other liabilities is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Insight Molecular Diagnostics is outperforming or lagging.

Tracking IMDX's other liabilities over time shows whether Insight Molecular Diagnostics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other liabilities page, Stockcircle has Insight Molecular Diagnostics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other liabilities (currently $0) with ownership activity and broader fundamentals.

Insight Molecular Diagnostics's other liabilities is $0; compare it with other Technology names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.

Questions & Answers